Preferred Name |
Basiliximab |
|
Synonyms |
BASILIXIMAB Basiliximab SDZ-CHI-621 Simulect |
|
Definitions |
A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes. |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C52186 |
|
CAS_Registry |
179045-86-4 |
|
code |
C52186 |
|
Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 |
|
Contributing_Source |
CTRP FDA |
|
DEFINITION |
A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes. |
|
Display_Name |
Basiliximab |
|
FDA_UNII_Code |
9927MT646M |
|
FULL_SYN |
BASILIXIMAB Basiliximab SDZ-CHI-621 Simulect |
|
Has_Target | ||
label |
Basiliximab |
|
Legacy Concept Name |
Basiliximab |
|
NCI_Drug_Dictionary_ID |
459956 |
|
PDQ_Closed_Trial_Search_ID |
459956 |
|
PDQ_Open_Trial_Search_ID |
459956 |
|
Preferred_Name |
Basiliximab |
|
prefixIRI |
Thesaurus:C52186 |
|
Semantic_Type |
Pharmacologic Substance |
|
UMLS_CUI |
C0676831 |
|
subClassOf |